Urgent.News

What's breaking now, across thousands of outlets.

AI

Nasdaq listing awaits Singapore’s US$1.5 billion AI drug-discovery biotech Nanyang Biologics

Its valuation is driven by a proprietary agentic AI platform and potential first-in-class cancer treatment

We haven't written up this one. The Business Times - Companies & Markets has the full story — the link below goes straight to it.

Read the original at businesstimes.com.sg →

More in AI

More from Wednesday 14 October →